# Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings

> **NCT05918809** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1031 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05918809
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-25
- **Primary completion:** 2022-06-17
- **Final completion:** 2022-06-17
- **Target enrollment:** 1031 (ACTUAL)
- **Last updated:** 2023-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918809, "Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings". Retrieved via AI Analytics 2026-09-11 from https://api.ai-analytics.org/clinical/NCT05918809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*